BeiGene
BGNE
#920
Rank
$21.65 B
Marketcap
$192.26
Share price
-1.03%
Change (1 day)
2.33%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : $3.36 Billion USD

According to BeiGene 's latest financial reports the company has $3.36 Billion USD in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$$3.53 B-19.3%
2022-12-31$$4.38 B-28.52%
2021-12-31$$6.13 B58.5%
2020-12-31$$3.86 B295.48%
2019-12-31$$0.97 B-44.21%
2018-12-31$$1.75 B156.29%
2017-12-31$$0.68 B93.88%
2016-12-31$$0.35 B374.85%
2015-12-31$$74.31 M188.42%
2014-12-31$$25.76 M-166.54%
2013-12-31$-$38.73 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
$6.01 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
$1.39 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA